

CURRICULUM VITAE JEDIDIAH INDIGO MORTON

March 13, 2025

Email: Jedidiah.Morton@monash.edu

Phone: 0403 487 378

Research Fellow

Monash University, Melbourne, Australia.

381 Royal Parade, Parkville, Victoria, Australia, 3052.

Contents

Professional appointments	2
Other positions	2
Qualifications	2
Competitive grant funding	2
Scholarships and awards	3
Publications	4
Textbook chapters	10
Invited lectures	10
Conference presentations	10
Invited articles	11
Supervision	11
Teaching	11
Peer review	12

Professional Appointments

2022-	Monash University. Research fellow.
2023-2024	Baker Heart and Diabetes Institute. Postdoctoral researcher.
2021-2022	Monash University. Teaching associate.
2019-2022	Monash University and Baker Heart and Diabetes Institute. PhD candidate.
2018-2019	Monash University. University of Melbourne. Research assistant.

Other positions

2024-2025	Lipoprotein(a) International Taskforce (ITF) Initiative. Health Economic Consultant.
2024-	Baker Heart and Diabetes Institute. Honorary appointment.
2023-	International Diabetes Federation, Diabetes Atlas Economic Impact of Diabetes Special Interest Group. Member.
2022-	GLOBODIAB study. Principal analyst.
2023-2024	Victorian Government, Department of Health, Safer Care Victoria Cardiovascular Learning Health Network Data Group. Member.
2022	Baker Heart and Diabetes Institute. Honorary appointment.

Qualifications

2022	Doctor of Philosophy, Monash University.
2018	Bachelor of Science (Honours), University of Melbourne.

Competitive grant funding

2025	Health Services Research Grant Program, HCF Research Foundation.	\$274,605.	CIA
2024	Postdoctoral Fellowship, The Heart Foundation.	\$151,200.	CIA.
2024	Charles Coghlan OAM Emerging Researcher Award, Diabetes Australia.	\$150,000.	CIA.
2023	45 and Up Cardiovascular Research Grant, The Heart Foundation.	\$120,000.	CIB.

Scholarships and Awards

2022	Finalist – Victorian Premier’s Awards for Health and Medical Research, Department of Health, Victorian Government.
2022	Damien Jolly Award for Higher Degree by Research Thesis Excellence, Monash University.
2022	Baker research prize for publication excellence, Baker Heart and Diabetes Institute.
2021	Finalist – Baker best publication award, Baker Heart and Diabetes Institute.
2021	Baker research prize for publication excellence, Baker Heart and Diabetes Institute.
2021	School of Public Health and Preventive Medicine best HDR paper award, Monash University.
2020	Finalist – Baker best publication award, Baker Heart and Diabetes Institute
2019-2022	Monash Graduate Excellence Scholarship, Monash University.
2019-2022	Australian Government Research Training Program Scholarship, Monash University.
2018	John A. McKenzie / Selby Scientific Foundation Award, University of Melbourne.
2017	Howitt Natural History Scholarship, University of Melbourne.
2016-2017	Dean’s Honours List, University of Melbourne.

Publications

1. Adam C Livori, Rasantha Kuruppumullage, Mardi Simmons, Aili Langford, Zanfina Ademi, J Simon Bell, Renee Dimond, and Jedidiah I Morton. Evaluating the implementation of a rapid access atrial fibrillation clinic utilising a pharmacist-physician model of care. *Research in Social and Administrative Pharmacy*, 2025.
2. Tamrat Befekadu Abebe, Jenni Ilomäki, Adam Livori, J Simon Bell, Jedidiah I Morton, and Zanfina Ademi. Current and Future Cost Burden of Myocardial Infarction in Australia: Dynamic Multistate Markov Model. *Journal of General Internal Medicine*, pages 1–10, 2025.
3. Melanie Lloyd, Jedidiah I Morton, Rachel L Peters, Paxton Loke, Sarah Ashley, Marcus S Shaker, Matthew Greenhawt, Zanfina Ademi, and Mimi LK Tang. Cost-effectiveness of oral immunotherapy for egg allergy according to age of therapy commencement. *The Journal of Allergy and Clinical Immunology: In Practice*, 2024.
4. Jedidiah I Morton, Danny Liew, Gerald F Watts, Sophia Zoungas, Stephen J Nicholls, Christopher M Reid, and Zanfina Ademi. Immediate Versus 5-Year Risk-Guided Initiation of Treatment for Primary Prevention of Cardiovascular Disease for Australians Aged 40 Years: A Health Economic Analysis. *Pharmacoeconomics*, pages 1–19, 2024.
5. Dianna J Magliano, Lei Chen, Jedidiah I Morton, Agus Salim, Bendix Carstensen, Edward W Gregg, Meda E Pavkov, Martti Arffman, Helen M Colhoun, Kyoung Hwa Ha, et al. Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium. *The Lancet Diabetes & Endocrinology*, 2024.
6. Dianna J Magliano, Lei Chen, Jedidiah I Morton, Oyunchimeg Buyadaa, Agus Salim, and Jonathan E Shaw. Changes in the incidence of type 2 diabetes in Australia, 2005–2019, overall and by socio-demographic characteristics: a population-based study. *Medical Journal of Australia*, 2024.
7. George SQ Tan, Judith C Maro, Shirley V Wang, Sengwee Toh, Jedidiah I Morton, Jenni Ilomäki, Jenna Wong, and Xiaojuan Li. Tree-based scan statistics to generate drug repurposing hypotheses: a test case using sodium-glucose cotransporter-2 inhibitors. *American Journal of Epidemiology*, page kwae355, 2024.
8. Dina Abushanab, Daoud Al-Badriyeh, Clara Marquina, Jedidiah I Morton, Melanie Lloyd, Ella Zomer, Stella Talic, Danny Liew, and Zanfina Ademi. The reduction of the productivity burden of cardiovascular disease by improving the risk factor control Among Australians with type 2 diabetes: a 10-year dynamic analysis. *European Journal of Preventive Cardiology*, page zwae292, 2024.
9. Jedidiah I Morton, Danny Liew, and Zanfina Ademi. A causal model for primary prevention of cardiovascular disease: the health economic model for the primary prevention of cardiovascular disease. *Value in Health*, 27(12):1743–1752, 2024.
10. Kanika Mehta, Dianna J Magliano, Bendix Carstensen, Agus Salim, Jedidiah I Morton, Julie Abimanyi-Ochom, Kaarin J Anstey, Jonathan E Shaw, and Julian W Sacre. Impact of type

- 2 diabetes and its duration on incidence rates of dementia death and medication prescription in the Australian population during 2003–2016. *Diabetes Research and Clinical Practice*, page 111795, 2024.
11. Adam C Livori, Zanfina Ademi, Jenni Ilomäki, Adam J Nelson, J Simon Bell, and Jedidiah I Morton. Patterns of 12-month post-myocardial infarction medication use according to revascularisation strategy: Analysis of 15,339 admissions in Victoria, Australia. *Heart, Lung and Circulation*, 33(10):1439–1449, 2024.
 12. Berhanu Elfu Feleke, Agus Salim, Jedidiah I Morton, Belinda J Gabbe, Dianna J Magliano, and Jonathan E Shaw. Excess Risk of Injury in Individuals With Type 1 or Type 2 Diabetes Compared With the General Population. *Diabetes care*, 47(8):1457–1462, 2024.
 13. Kate ED Ziser, Adam C Livori, Jedidiah I Morton, Adaire Prosser, Jenni Ilomäki, and Stephen J Wood. Acute kidney injury, renal impairment and renal failure associated with sodium glucose co-transporter-2 inhibitors in at-risk groups: A systematic review. *British Journal of Clinical Pharmacology*, 90(7):1541–1558, 2024.
 14. Kate ED Ziser, Stephen Wood, George SQ Tan, Jedidiah I Morton, Jonathan E Shaw, J Simon Bell, and Jenni Ilomaki. The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort study. *Journal of Diabetes*, 16(4):e13507, 2024.
 15. Tamrat Befekadu Abebe, Jedidiah I Morton, Jenni Ilomaki, and Zanfina Ademi. Future burden of ischemic stroke in Australia: impact on health outcomes between 2019 and 2038. *Neuroepidemiology*, 58(6):449–459, 2024.
 16. Tamrat Befekadu Abebe, Jenni Ilomaki, Adam Livori, J Simon Bell, Jedidiah I Morton, and Zanfina Ademi. Current and Future Cost Burden of Ischemic Stroke in Australia: Dynamic Model. *Neuroepidemiology*, 58(5):358–368, 2024.
 17. Hannah Doody, Justine Ayre, Adam Livori, Jenni Ilomäki, Viviane Khalil, J Simon Bell, and Jedidiah I Morton. The Impact of Frailty on Initiation, Continuation and Discontinuation of Secondary Prevention Medications Following Myocardial Infarction. *Archives of gerontology and geriatrics*, 122:105370, 2024.
 18. Clara Marquina, Jedidiah I Morton, Melanie Lloyd, Dina Abushanab, Yeji Baek, Tamrat Abebe, Adam Livori, Padam Dahal, Gerald F Watts, and Zanfina Ademi. Cost-effectiveness of screening strategies for familial hypercholesterolaemia: An updated systematic review. *PharmacoEconomics*, 42(4):373–392, 2024.
 19. Jedidiah I Morton, Jenni Ilomäki, Stephen J Wood, Shin J Liao, Michelle Steeper, Hannah Doody, and J Simon Bell. The effect of frailty on post-discharge management and outcomes of acute glycaemic crises: Analysis of admissions for hypoglycaemia and hyperglycaemia in Australia. *Diabetes Research and Clinical Practice*, page 111572, 2024.
 20. George SQ Tan, Jedidiah I Morton, Stephen Wood, Jonathan E Shaw, Dianna J Magliano, and Jenni Ilomäki. SGLT-2 Inhibitor Use and Cause-Specific Hospitalization Rates: An Outcome-Wide Study to Identify Novel Associations of SGLT-2 Inhibitors. *Clinical Pharmacology & Therapeutics*, 115(6):1304–1315, 2024.

21. George SQ Tan, Jedidiah I Morton, Stephen Wood, Natalie L Trevaskis, Dianna J Magliano, John Windsor, Jonathan E Shaw, and Jenni Ilomäki. COX2 inhibitor use and type 2 diabetes treatment intensification: A registry-based cohort study. *Diabetes Research and Clinical Practice*, 207:111082, 2024.
22. Adam C Livori, Zanfina Ademi, Jenni Ilomäki, Derk Pol, Jedidiah I Morton, and J Simon Bell. No effect of remoteness on clinical outcomes following myocardial infarction: An analysis of 43,729 myocardial infarctions in Victoria, Australia. *International Journal of Cardiology*, 398:131593, 2024.
23. Adam C Livori, Zanfina Ademi, Jenni Ilomäki, Derk Pol, Jedidiah I Morton, and J Simon Bell. Use of secondary prevention medications in metropolitan and non-metropolitan areas: an analysis of 41 925 myocardial infarctions in australia. *European Journal of Preventive Cardiology*, 31(5):580–588, 2024.
24. Clara Marquina, Jedidiah I Morton, and Zanfina Ademi. Health economics of detection and treatment of children with familial hypercholesterolemia: To screen or not to screen is no longer the question. *Current Opinion in Endocrinology, Diabetes and Obesity*, 31(2):84–89, 2024.
25. Berhanu Elfu Feleke, Jedidiah Morton, Dianna Magliano, and Jonathan E Shaw. Trends of hospitalisation for cardiovascular diseases among people with diabetes in Australia. *Diabetes Research and Clinical Practice*, 205:110973, 2023.
26. Louise Lord, Mark Hew, Miriam TY. Leung, Jedidiah I. Morton, and Jenni Ilomäki. Medication use in people with cystic fibrosis before and after modulator therapy. *Pulmonary Pharmacology & Therapeutics*, 83:102264, 2023.
27. Tamrat Befekadu Abebe, Jedidiah I Morton, Jenni Ilomaki, and Zanfina Ademi. Future burden of myocardial infarction in australia: impact on health outcomes between 2019 and 2038. *European Heart Journal-Quality of Care and Clinical Outcomes*, 10(5):421–430, 2024.
28. Jedidiah I Morton, Clara Marquina, Melanie Lloyd, Gerald F Watts, Sophia Zoungas, Danny Liew, and Zanfina Ademi. Lipid-lowering strategies for primary prevention of coronary heart disease in the uk: a cost-effectiveness analysis. *Pharmacoeconomics*, 42(1):91–107, 2024.
29. Jedidiah I Morton, Bendix Carstensen, Stephen P McDonald, Kevan R Polkinghorne, Jonathan E Shaw, and Dianna J Magliano. Trends in the Incidence of End-Stage Kidney Disease in Type 1 and Type 2 Diabetes in Australia, 2010-2019. *American Journal of Kidney Diseases*, 82(5):608–616, 2023.
30. Hannah Doody, Adam Livori, Justine Ayre, Zanfina Ademi, J Simon Bell, and Jedidiah I Morton. Guideline concordant prescribing following myocardial infarction in people who are frail: a systematic review. *Archives of Gerontology and Geriatrics*, 114:105106, 2023.
31. Clara Marquina, Jedidiah Morton, Tom Brett, Melanie Lloyd, Jan Radford, Clare Heal, Charlotte Hespe, Gerard Gill, David Sullivan, Ella Zomer, et al. Enhancing the detection and care of heterozygous familial hypercholesterolemia in primary care: cost-effectiveness and return on investment. *Circulation: Genomic and Precision Medicine*, 16(3):267–274, 2023.

32. Dina Abushanab, Clara Marquina, Jedidiah I Morton, Daoud Al-Badriyeh, Melanie Lloyd, Dianna J Magliano, Danny Liew, and Zanfina Ademi. Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022–2031. *Pharmacoeconomics*, 41(6):719–732, 2023.
33. Melanie Lloyd, Jedidiah Morton, Helena Teede, Clara Marquina, Dina Abushanab, Dianna J Magliano, Emily J Callander, and Zanfina Ademi. Long-term cost-effectiveness of implementing a lifestyle intervention during pregnancy to reduce the incidence of gestational diabetes and type 2 diabetes. *Diabetologia*, 66(7):1223–1234, 2023.
34. Jedidiah I Morton, Clara Marquina, Dianna J Magliano, Jonathan E Shaw, and Zanfina Ademi. Targeting diabetes prevention to more disadvantaged groups improves cost-effectiveness: Implications of inequality in type 2 diabetes from theoretical interventions. *Value in Health*, 26(7):974–983, 2023.
35. Dunya Tomic, Jedidiah I Morton, Agus Salim, Tim Lambert, Dianna J Magliano, and Jonathan E Shaw. Hospitalisation for mental health disorders in Australians with type 1 or type 2 diabetes. *Diabetes Research and Clinical Practice*, 196:110244, 2023.
36. Peter A Lazzarini, Susanna M Cramb, Jonathan Golledge, Jedidiah I Morton, Dianna J Magliano, and Jaap J Van Netten. Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century. *Diabetologia*, 66(2):267–287, 2023.
37. Matthew Quigley, Jedidiah I Morton, Peter A Lazzarini, Sophia Zoungas, Jonathan E Shaw, and Dianna J Magliano. Trends in diabetes-related foot disease hospitalizations and amputations in Australia, 2010 to 2019. *Diabetes Research and Clinical Practice*, 194:110189, 2022.
38. C Marquina, J Morton, E Zomer, S Talic, S Lybrand, D Thomson, D Liew, and Z Ademi. Lost therapeutic benefit of delayed LDL-C control in statin treated patients and cost-effectiveness analysis of lipid-lowering intensification. *Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research*, pages S1098–3015, 2022.
39. Jedidiah I Morton, Clara Marquina, Jonathan E Shaw, Danny Liew, Kevan R Polkinghorne, Zanfina Ademi, and Dianna J Magliano. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. *Diabetologia*, 66(4):642–656, 2023.
40. Dunya Tomic, Agus Salim, Jedidiah I Morton, Dianna J Magliano, and Jonathan E Shaw. Reasons for hospitalisation in Australians with type 2 diabetes compared to the general population, 2010–2017. *Diabetes Research and Clinical Practice*, 194:110143, 2022.
41. Dunya Tomic, Jedidiah I Morton, Lei Chen, Agus Salim, Edward W Gregg, Meda E Pavkov, Martti Arffman, Ran Balicer, Marta Baviera, Elise Boersma-van Dam, et al. Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study. *The Lancet Diabetes & Endocrinology*, 10(11):795–803, 2022.

42. Jedidiah I Morton, Danny Liew, Stephen J Nicholls, and Zanfina Ademi. Should we continue to subsidise therapeutics with uncertain efficacy? Health economic implications for icosapent ethyl. *European Journal of Preventive Cardiology*, 30(17):1935–1938, 2023.
43. Zanfina Ademi, Jedidiah I Morton, Danny Liew, Stephen J Nicholls, Sophia Zoungas, and Brian A Ference. Integrating the biology of cardiovascular disease into the epidemiology of economic decision modelling via mendelian randomisation. *Pharmacoeconomics*, 40(11):1033–1042, 2022.
44. Jedidiah I Morton, Peter A Lazzarini, Kevan R Polkinghorne, Bendix Carstensen, Dianna J Magliano, and Jonathan E Shaw. The association of attained age, age at diagnosis, and duration of type 2 diabetes with the long-term risk for major diabetes-related complications. *Diabetes Research and Clinical Practice*, 190:110022, 2022.
45. Jedidiah I Morton, Jenni Ilomäki, Dianna J Magliano, and Jonathan E Shaw. Persistent disparities in diabetes medication receipt by socio-economic disadvantage in Australia. *Diabetic Medicine*, 39(9):e14898, 2022.
46. Jedidiah I Morton, Jenni Ilomäki, Stephen J Wood, J Simon Bell, Quan Huynh, Dianna J Magliano, and Jonathan E Shaw. Treatment gaps, 1-year readmission and mortality following myocardial infarction by diabetes status, sex and socioeconomic disadvantage. *J Epidemiol Community Health*, 76(7):637–645, 2022.
47. Oyunchimeg Buyadaa, Agus Salim, Jedidiah I Morton, Karin Jandeleit-Dahm, Dianna J Magliano, and Jonathan E Shaw. Examining the factors contributing to the association between non-albuminuric CKD and a low rate of kidney function decline in diabetes. *Therapeutic Advances in Endocrinology and Metabolism*, 13:20420188221083518, 2022.
48. Paz LD Ruiz, Lei Chen, Jedidiah I Morton, Agus Salim, Bendix Carstensen, Edward W Gregg, Meda E Pavkov, Manel Mata-Cases, Didac Mauricio, Gregory A Nichols, et al. Mortality trends in type 1 diabetes: a multicountry analysis of six population-based cohorts. *Diabetologia*, 65(6):964–972, 2022.
49. Jedidiah I Morton, Peter A Lazzarini, Jonathan E Shaw, and Dianna J Magliano. Trends in the incidence of hospitalization for major diabetes-related complications in people with type 1 and type 2 diabetes in Australia, 2010–2019. *Diabetes care*, 45(4):789–797, 2022.
50. Jedidiah I Morton, Jenni Ilomäki, Stephen J Wood, J Simon Bell, Jonathan E Shaw, and Dianna J Magliano. One-year readmission and mortality following ischaemic stroke by diabetes status, sex, and socioeconomic disadvantage: an analysis of 27,802 strokes from 2012 to 2017. *Journal of the Neurological Sciences*, 434:120149, 2022.
51. Kaitlyn Hastings, Clara Marquina, Jedidiah Morton, Dina Abushanab, Danielle Berkovic, Stella Talic, Ella Zomer, Danny Liew, and Zanfina Ademi. Projected new-onset cardiovascular disease by socioeconomic group in australia. *Pharmacoeconomics*, pages 1–12, 2022.
52. Jedidiah I Morton, Julian W Sacre, Stephen P McDonald, Dianna J Magliano, and Jonathan E Shaw. Excess all-cause and cause-specific mortality for people with diabetes and end-stage kidney disease. *Diabetic Medicine*, 39(6):e14775, 2022.

53. Jessica L Harding, Jedidiah I Morton, Jonathan E Shaw, Rachel E Patzer, Stephen P McDonald, and Dianna J Magliano. Changes in excess mortality among adults with diabetes-related end-stage kidney disease: a comparison between the USA and Australia. *Nephrology Dialysis Transplantation*, 37(10):2004–2013, 2022.
54. Oyunchimeg Buyadaa, Agus Salim, Jedidiah I Morton, Dianna J Magliano, and Jonathan E Shaw. Rate of decline in kidney function and known age-of-onset or duration of type 2 diabetes. *Scientific Reports*, 11(1):14705, 2021.
55. Jedidiah I Morton, Stephen P McDonald, Agus Salim, Danny Liew, Jonathan E Shaw, and Dianna J Magliano. Projecting the Incidence of Type 2 Diabetes–Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment. *Diabetes Care*, 44(7):1515–1523, 2021.
56. Jedidiah I Morton, Jenni Ilomäki, Dianna J Magliano, and Jonathan E Shaw. The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study. *Diabetologia*, 64:349–360, 2021.
57. Jedidiah I Morton, Danny Liew, Stephen P McDonald, Jonathan E Shaw, and Dianna J Magliano. The association between age of onset of type 2 diabetes and the long-term risk of end-stage kidney disease: a national registry study. *Diabetes Care*, 43(8):1788–1795, 2020.

Textbook chapters

1. Papadimos E, Morton JJ, Harding JL, Barr E. A Life Course Approach to Diabetes. In Mishra G, Hardy R, Kuh D, A Life Course Approach to Women's Health (2nd edition). Oxford University Press.

Invited lectures

1. Steno Diabetes Center, Copenhagen, Denmark. "Creative use of large datasets to improve diabetes outcomes". April 2024.
2. The Society of Hospital Pharmacists of Australia (SHPA) – Medicines Management 2023. "RCT or bust". November 2023.
3. Deakin University, Melbourne, Australia. "Inequality in type 2 diabetes in Australia". June 2023.
4. Buloke Loddon Gannawarra Diabetes Online Forum, Victoria, Australia. "Up-to-date diabetes treatment? Depends on where you live." January 2022.

Conference presentations

1. Morton JJ, Liew D, Watts GF, Zoungas S, Nicholls SJ, Reid CM, Ademi Z. Immediate vs. 5-year risk-guided Initiation of treatment for Primary Prevention of Cardiovascular Disease in 40-year-old Australians. Cardiac Society of Australia and New Zealand, August 2024.
2. Morton JJ, Liew D, Watts GF, Zoungas S, Nicholls SJ, Reid CM, Ademi Z. Cost-effectiveness of immediate vs. 5-year risk-guided initiation of treatment for primary prevention of cardiovascular disease in 40-year-old Australians. Cardiac Society of Australia and New Zealand, August 2024.
3. Morton JJ, Magliano DJ, Chen L, Sacre JW, Carstensen B, Gregg EW, Pavkov ME, Arffman M, Chu LM, Eeg-Olofsson K, Fleetwood K, Fosse-Edorh S, Guion M, Gurevicius R, Ha KH, Kaul P, Keskimäki I, Kim DJ, Laurberg T, Støvring H, Wild SH, Shaw JE. Cause-specific Mortality Trends in People With and Without Diabetes: A Multi-Country Analysis. European Diabetes Epidemiology Group. April 2024.
4. Morton JJ, Marquina C, Lloyd M, Watts GF, Zoungas S, Liew D, Ademi Z. Lipid Lowering Strategies for Primary Prevention of Coronary Heart Disease in Australia: A Cost-effectiveness Analysis Using Mendelian Randomisation. Cardiac Society of Australia and New Zealand, August 2023.
5. Morton JJ, Lazzarini PA, Polkinghorne KR, Carstensen B, Magliano DJ, Shaw JE. The Association between Age of Onset of Type 2 Diabetes and the Long-Term Risk for Major Diabetes-Related Complications. American Diabetes Association, June 2022.
6. Morton JJ, Marquina C, Shaw JE, Liew D, Ademi Z, Magliano DJ. Projecting the Incidence and Costs of Major Cardiorenal complications of Type 2 diabetes with Widespread GLP-1

RA and SGLT2i use. International Society for Pharmacoeconomics and Outcomes Research, May 2022.

7. Morton JI, Ilomäki J, Wood SJ, Magliano DJ, Shaw JE. Trends in Rehospitalisation Rates for Myocardial Infarction, Heart Failure, and Stroke in People with and without Diabetes in Australia from 2012-2018. American Diabetes Association, June 2021.
8. Morton JI, McDonald SP, Salim A, Liew D, Shaw JE, Magliano DJ. Projecting the Future Incidence of Type 2 Diabetes-Related End-Stage Kidney Disease: A Comparison between Diabetes Prevention and Treatment. Australasian Diabetes Congress 2020.
9. Morton JI, Liew D, McDonald SP, Shaw JE, Magliano DJ. The Association of Age of Onset of Type 2 Diabetes with Long-Term Risk of End Stage Kidney Disease: A National Registry Study. American Diabetes Association, June 2020.

Invited articles

1. Morton JI. Sweet Saviour: Increasing availability of a new diabetes medication could prevent many people with type 2 diabetes developing kidney failure. Diabetic Living (readership: 245,000; circulation: 56,739), 2021.

Supervision

1. Della Wang. Doctor of Philosophy. Monash University. Associate supervisor.
2. Sheridan Rodda. Doctor of Philosophy. Monash University. Associate supervisor.
3. Tamrat Befekadu Abebe. Doctor of Philosophy. Monash University. Associate supervisor.
4. Adam Livori. Doctor of Philosophy. Monash University. Associate supervisor.
5. George Tan. Doctor of Philosophy. Monash University. Associate supervisor.
6. Hannah Doody. Masters of Clinical Pharmacy. Monash University. Primary supervisor.
7. Anthony Horton. Masters of Public Health. Monash University. Primary supervisor.

Teaching

1. Victorian Heart Hospital. Introductory Biostatistics. Course designer and teacher. 2024.
2. The Society of Hospital Pharmacists of Australia (SHPA) – Medicines Management 2023. “Doing valuable research”. Course designer and teacher. 2023.
3. Baker Heart and Diabetes Institute. Multistate models: Occurrence rates, cumulative risks, competing risks, state probabilities with multiple states and time scales using R and Epi::Lexis, by Bendix Carstensen. Teaching assistant. 2023.

4. Monash University. MPS5304: Regulatory science and monitoring medicine use (Master of Clinical Pharmacy). Guest lecturer. 2022.
5. Monash University. PGC5101: Evidence based practice (Master of Clinical Pharmacy). Teaching associate and interim unit coordinator. 2021-2022.
6. Monash University. PHR2012: Professional Practice IV (Bachelor of Pharmacy). Teaching associate. 2021-2022.
7. Monash University. BMS4200: Biostatistics for Biomedicine (Honours). Teaching associate. 2021.

Peer review

I have reviewed manuscripts for the following journals:

- The Lancet Diabetes and Endocrinology
- European Heart Journal
- Annals of Internal Medicine
- Diabetes Care
- Medical Journal of Australia
- European Journal of Preventive Cardiology
- Diabetologia
- American Journal of Kidney Diseases
- The Lancet Regional Health – Western Pacific
- Cardiovascular Diabetology
- Diabetes Research and Clinical Practice
- Diabetes & Metabolism
- Diabetic Medicine
- Diabetes, Obesity and Metabolism
- Value in Health
- Pharmacoeconomics
- BMJ Open
- Frontiers in Endocrinology
- Scientific Reports

- European Journal of Clinical Investigation
- Annals of Medicine
- Journal of Epidemiology and Community Health
- GeroScience
- Journal of Clinical Lipidology
- BMC Nephrology
- BMC Public Health
- BMC Health Services Research
- Current Medical Research & Opinion
- Health Economics Review
- Journal of Pharmacy Practice and Research

I have reviewed grants for the following schemes:

- Heart Foundation Postdoctoral Fellowship.
- Gold Coast Health Collaborative Research Grant Scheme.